Sugi Predict

Sugi Predict / Compounds / SCHEMBL2297635

SCHEMBL2297635

SCHEMBL2297635

Cc1ccc(COC(N)=O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 1/20 0.54
▸ AGXT P21549 2/20 0.54
▸ RAB9A P51151 4/20 0.53
▸ NPC1 O15118 2/20 0.53
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ MMP2 P08253 2/20 0.49
▸ MMP12 P39900 2/20 0.49
▸ MMP1 P03956 1/20 0.49
▸ MMP9 P14780 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ MAOB P27338 2/20 0.47
▸ P2RX4 Q99571 1/20 0.46
▸ NAAA Q02083 1/20 0.45
▸ ALOX15 P16050 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ NPY1R P25929 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30437401 0.89 KMT2A (0.50) PARP10CA2ALDH1A1MAPK1ALOX15
SCHEMBL16181954 0.88 GAA (0.52) PARP10RAB9ANPC1CA1CA2
SCHEMBL143772 0.83 MEN1 (0.61) CA2CA9ALDH1A1KDM4EL3MBTL1
SCHEMBL6646548 0.83 AGXT (0.52) PARP10AGXTRAB9ANPC1CA1
SCHEMBL26555 0.83 AGXT (0.52) PARP10AGXTRAB9ANPC1CA1
SCHEMBL1934595 0.81 KMT2A (0.44) PARP10CA1CA2CA9ALDH1A1
SCHEMBL873414 0.81 ALDH1A1 (0.67) PARP10AGXTRAB9ANPC1CA1
P-Xylene SCHEMBL9685877 0.81 ALDH1A1 (0.67) PARP10AGXTRAB9ANPC1CA1
SCHEMBL5709288 0.81 TPSAB1 (0.51) PARP10ALDH1A1MAOB
SCHEMBL5369370 0.81 ALDH1A1 (0.50) PARP10AGXTRAB9ANPC1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121226193-A Trifluoro-methoxy method for synthesizing wei 江苏海洋大学 2025-12-30 — — CN disclosed
CN-117965536-A Oligonucleotide compositions and methods thereof 波涛生命科学有限公司 2024-05-03 — — CN disclosed
CN-117915918-A Soluble adenylate cyclase (sAC) inhibitors and uses thereof 康奈尔大学 2024-04-19 — — CN disclosed
EP-3665161-B1 NEW TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2023-09-27 — — EP disclosed
CN-111757735-B Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2023-09-22 — — CN disclosed
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. 2023-08-03 — — US disclosed
US-20230010108-A1 A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-01-12 — — US disclosed
CN-114401719-A Inhibitors of cyclin-dependent kinase 7 and uses thereof 达纳-法伯癌症研究所股份有限公司 2022-04-26 — — CN disclosed
CN-108368101-B Selective NR2B antagonists 百时美施贵宝公司 2022-03-15 — — CN disclosed
CN-113164477-A Pyrazolopyridine inhibitors of C-JUN-N-terminal kinase and uses thereof 达纳-法伯癌症研究所股份有限公司 2021-07-23 — — CN disclosed
US-7205291-B2 High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-17 — — US disclosed
US-RE39420-E1 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-12-05 — — US disclosed
CN-1518445-A Treatment of sexual dysfunction 沃纳-兰伯特公司 2004-08-04 — — CN disclosed
EP-0826673-B1 ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO (JP) 2002-11-20 — — EP disclosed
US-6462076-B2 CYSTEINE PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CYSTEINE PROTEASES, SUCH AS OSTEOPOROSIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, TUMOR METASTASIS, ANGINA PECTORIS, PLAQUE RUPTURE AND STROKE ETC. HOFFMANN-LA ROCHE INC. 2002-10-08 — — US disclosed
CN-1345313-A Pesticidal enantiomer-pure 2,4-disubstituted oxazolines NOVARTIS AG (CH) 2002-04-17 — — CN disclosed
US-5972946-A NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1999-10-26 — — US disclosed
US-5908858-A OSTEOPOROSIS; LEUKOTRIENE INHIBITOR SANKYO COMPANY, LIMITED (JP) 1999-06-01 — — US disclosed
EP-0826673-A1 ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1998-03-04 — — EP disclosed
EP-0799823-A1 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1997-10-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230010108-A1 A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP DAO, DDO, DCLRE1A PARP10 847/4885AGXT 2994/4885RAB9A 4057/4885
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF NDC1, KIFC1, SDCBP PARP10 3640/4885AGXT 2996/4885RAB9A 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.